nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—ABCC5—Fluorouracil—skin cancer	0.366	0.675	CbGbCtD
Alprostadil—ABCC4—Fluorouracil—skin cancer	0.176	0.325	CbGbCtD
Alprostadil—PTGER2—Prostanoid ligand receptors—PTGER4—skin cancer	0.0116	0.0807	CbGpPWpGaD
Alprostadil—PTGER1—Prostanoid ligand receptors—PTGER4—skin cancer	0.00785	0.0545	CbGpPWpGaD
Alprostadil—PTGIR—Prostanoid ligand receptors—PTGER4—skin cancer	0.00785	0.0545	CbGpPWpGaD
Alprostadil—PTGER2—Eicosanoid ligand-binding receptors—PTGER4—skin cancer	0.00772	0.0536	CbGpPWpGaD
Alprostadil—Misoprostol—PTGER4—skin cancer	0.00715	0.45	CrCbGaD
Alprostadil—PTGER2—Small Ligand GPCRs—PTGER4—skin cancer	0.00639	0.0444	CbGpPWpGaD
Alprostadil—PTGIR—endothelium—skin cancer	0.00622	0.0786	CbGeAlD
Alprostadil—Azelaic Acid—TYR—skin cancer	0.00608	0.383	CrCbGaD
Alprostadil—PTGIR—blood vessel—skin cancer	0.00574	0.0725	CbGeAlD
Alprostadil—PTGIR—Eicosanoid ligand-binding receptors—PTGER4—skin cancer	0.00521	0.0362	CbGpPWpGaD
Alprostadil—PTGER1—Eicosanoid ligand-binding receptors—PTGER4—skin cancer	0.00521	0.0362	CbGpPWpGaD
Alprostadil—ABCC5—hair follicle—skin cancer	0.00489	0.0618	CbGeAlD
Alprostadil—PTGER2—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.00443	0.0308	CbGpPWpGaD
Alprostadil—PTGER2—Ovarian Infertility Genes—MLH1—skin cancer	0.00437	0.0304	CbGpPWpGaD
Alprostadil—PTGIR—Small Ligand GPCRs—PTGER4—skin cancer	0.00432	0.03	CbGpPWpGaD
Alprostadil—PTGER1—Small Ligand GPCRs—PTGER4—skin cancer	0.00432	0.03	CbGpPWpGaD
Alprostadil—ABCC5—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00427	0.0297	CbGpPWpGaD
Alprostadil—PTGER2—mammalian vulva—skin cancer	0.00414	0.0523	CbGeAlD
Alprostadil—SLCO3A1—nipple—skin cancer	0.00366	0.0463	CbGeAlD
Alprostadil—SLCO2A1—nipple—skin cancer	0.00363	0.0458	CbGeAlD
Alprostadil—SLCO2A1—neck—skin cancer	0.00359	0.0453	CbGeAlD
Alprostadil—PTGER2—female reproductive system—skin cancer	0.00354	0.0448	CbGeAlD
Alprostadil—PTGER1—female reproductive system—skin cancer	0.00336	0.0424	CbGeAlD
Alprostadil—PTGIR—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.003	0.0208	CbGpPWpGaD
Alprostadil—PTGER1—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.003	0.0208	CbGpPWpGaD
Alprostadil—ABCC4—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00296	0.0206	CbGpPWpGaD
Alprostadil—PTGIR—connective tissue—skin cancer	0.00294	0.0372	CbGeAlD
Alprostadil—PTGER1—head—skin cancer	0.00281	0.0355	CbGeAlD
Alprostadil—PTGIR—epithelium—skin cancer	0.00279	0.0353	CbGeAlD
Alprostadil—SLCO2A1—epithelium—skin cancer	0.00244	0.0308	CbGeAlD
Alprostadil—SLCO2A1—skin of body—skin cancer	0.00232	0.0293	CbGeAlD
Alprostadil—PTGER2—Ovarian Infertility Genes—CDK4—skin cancer	0.00222	0.0155	CbGpPWpGaD
Alprostadil—PTGER2—G alpha (s) signalling events—MC1R—skin cancer	0.00217	0.0151	CbGpPWpGaD
Alprostadil—SLCO3A1—mammalian vulva—skin cancer	0.00214	0.027	CbGeAlD
Alprostadil—SLCO2A1—mammalian vulva—skin cancer	0.00212	0.0268	CbGeAlD
Alprostadil—PTGIR—female reproductive system—skin cancer	0.00208	0.0262	CbGeAlD
Alprostadil—PTGER2—lymph node—skin cancer	0.00207	0.0262	CbGeAlD
Alprostadil—Dinoprostone—PTGER4—skin cancer	0.00201	0.126	CrCbGaD
Alprostadil—SLCO3A1—female reproductive system—skin cancer	0.00183	0.0231	CbGeAlD
Alprostadil—SLCO2A1—female reproductive system—skin cancer	0.00181	0.0229	CbGeAlD
Alprostadil—PTGIR—head—skin cancer	0.00173	0.0219	CbGeAlD
Alprostadil—PTGER2—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.00167	0.0116	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00163	0.0114	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00155	0.0108	CbGpPWpGaD
Alprostadil—SLCO3A1—head—skin cancer	0.00153	0.0193	CbGeAlD
Alprostadil—SLCO2A1—head—skin cancer	0.00152	0.0191	CbGeAlD
Alprostadil—ABCC5—Fluoropyrimidine Activity—ERCC2—skin cancer	0.0015	0.0104	CbGpPWpGaD
Alprostadil—PTGIR—G alpha (s) signalling events—MC1R—skin cancer	0.00146	0.0102	CbGpPWpGaD
Alprostadil—PTGER2—G alpha (s) signalling events—PTGER4—skin cancer	0.00142	0.0099	CbGpPWpGaD
Alprostadil—Back pain—Vismodegib—skin cancer	0.00138	0.00631	CcSEcCtD
Alprostadil—Muscle spasms—Vismodegib—skin cancer	0.00137	0.00627	CcSEcCtD
Alprostadil—Nasal congestion—Imiquimod—skin cancer	0.00137	0.00627	CcSEcCtD
Alprostadil—ABCC5—Defective B3GAT3 causes JDSSDHD—CSPG4—skin cancer	0.00136	0.00947	CbGpPWpGaD
Alprostadil—Injury—Imiquimod—skin cancer	0.00136	0.00621	CcSEcCtD
Alprostadil—SLCO2B1—female reproductive system—skin cancer	0.0013	0.0164	CbGeAlD
Alprostadil—Lethargy—Imiquimod—skin cancer	0.00128	0.00583	CcSEcCtD
Alprostadil—Pain in extremity—Imiquimod—skin cancer	0.00125	0.00571	CcSEcCtD
Alprostadil—PTGIR—lymph node—skin cancer	0.00121	0.0153	CbGeAlD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00121	0.00838	CbGpPWpGaD
Alprostadil—Wheezing—Bleomycin—skin cancer	0.00119	0.00543	CcSEcCtD
Alprostadil—ABCC4—female reproductive system—skin cancer	0.00115	0.0145	CbGeAlD
Alprostadil—Numbness—Fluorouracil—skin cancer	0.00115	0.00524	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Temozolomide—skin cancer	0.00113	0.00518	CcSEcCtD
Alprostadil—Skin disorder—Vismodegib—skin cancer	0.00113	0.00517	CcSEcCtD
Alprostadil—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.00113	0.00785	CbGpPWpGaD
Alprostadil—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.00113	0.00785	CbGpPWpGaD
Alprostadil—Sensory loss—Fluorouracil—skin cancer	0.0011	0.00501	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—PTCH2—skin cancer	0.00109	0.00756	CbGpPWpGaD
Alprostadil—SLCO2B1—head—skin cancer	0.00108	0.0137	CbGeAlD
Alprostadil—Influenza—Imiquimod—skin cancer	0.00108	0.00493	CcSEcCtD
Alprostadil—SLCO3A1—lymph node—skin cancer	0.00107	0.0135	CbGeAlD
Alprostadil—SLCO2A1—lymph node—skin cancer	0.00106	0.0134	CbGeAlD
Alprostadil—Sweating increased—Imiquimod—skin cancer	0.00105	0.00481	CcSEcCtD
Alprostadil—Supraventricular tachycardia—Docetaxel—skin cancer	0.00105	0.00478	CcSEcCtD
Alprostadil—ABCC4—Fluoropyrimidine Activity—ERCC2—skin cancer	0.00104	0.00723	CbGpPWpGaD
Alprostadil—Bronchitis—Imiquimod—skin cancer	0.00104	0.00474	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00103	0.00718	CbGpPWpGaD
Alprostadil—Dyspepsia—Vismodegib—skin cancer	0.00103	0.00469	CcSEcCtD
Alprostadil—Redness—Docetaxel—skin cancer	0.00102	0.00464	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Imiquimod—skin cancer	0.001	0.00459	CcSEcCtD
Alprostadil—Influenza like illness—Temozolomide—skin cancer	0.001	0.00458	CcSEcCtD
Alprostadil—Pain—Vismodegib—skin cancer	0.000997	0.00455	CcSEcCtD
Alprostadil—Sepsis—Dactinomycin—skin cancer	0.00099	0.00452	CcSEcCtD
Alprostadil—Burning sensation—Docetaxel—skin cancer	0.000988	0.00451	CcSEcCtD
Alprostadil—ABCC5—lymph node—skin cancer	0.000971	0.0123	CbGeAlD
Alprostadil—Injury—Bleomycin—skin cancer	0.000966	0.00441	CcSEcCtD
Alprostadil—PTGIR—G alpha (s) signalling events—PTGER4—skin cancer	0.000962	0.00669	CbGpPWpGaD
Alprostadil—ABCC4—head—skin cancer	0.000961	0.0121	CbGeAlD
Alprostadil—Acute coronary syndrome—Imiquimod—skin cancer	0.00095	0.00434	CcSEcCtD
Alprostadil—Myocardial infarction—Imiquimod—skin cancer	0.000944	0.00431	CcSEcCtD
Alprostadil—Urinary tract infection—Imiquimod—skin cancer	0.000936	0.00428	CcSEcCtD
Alprostadil—Abdominal pain—Vismodegib—skin cancer	0.000922	0.00421	CcSEcCtD
Alprostadil—Sinusitis—Imiquimod—skin cancer	0.000904	0.00413	CcSEcCtD
Alprostadil—Abnormal vision—Temozolomide—skin cancer	0.0009	0.00411	CcSEcCtD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000898	0.00624	CbGpPWpGaD
Alprostadil—Erythema—Vemurafenib—skin cancer	0.000883	0.00403	CcSEcCtD
Alprostadil—Haemoglobin—Imiquimod—skin cancer	0.000869	0.00397	CcSEcCtD
Alprostadil—Rhinitis—Imiquimod—skin cancer	0.000867	0.00396	CcSEcCtD
Alprostadil—Haemorrhage—Imiquimod—skin cancer	0.000865	0.00395	CcSEcCtD
Alprostadil—Pharyngitis—Imiquimod—skin cancer	0.000858	0.00392	CcSEcCtD
Alprostadil—Back pain—Vemurafenib—skin cancer	0.000854	0.0039	CcSEcCtD
Alprostadil—Urethral disorder—Imiquimod—skin cancer	0.000848	0.00387	CcSEcCtD
Alprostadil—Lethargy—Dactinomycin—skin cancer	0.000845	0.00386	CcSEcCtD
Alprostadil—Asthenia—Vismodegib—skin cancer	0.000837	0.00382	CcSEcCtD
Alprostadil—Visual impairment—Imiquimod—skin cancer	0.000833	0.00381	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00083	0.00577	CbGpPWpGaD
Alprostadil—Sepsis—Fluorouracil—skin cancer	0.000825	0.00377	CcSEcCtD
Alprostadil—Pruritus—Vismodegib—skin cancer	0.000825	0.00377	CcSEcCtD
Alprostadil—Nasal congestion—Temozolomide—skin cancer	0.000822	0.00376	CcSEcCtD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000814	0.00566	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000814	0.00566	CbGpPWpGaD
Alprostadil—Flushing—Imiquimod—skin cancer	0.000803	0.00366	CcSEcCtD
Alprostadil—Diarrhoea—Vismodegib—skin cancer	0.000798	0.00364	CcSEcCtD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000793	0.00551	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000787	0.00547	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—MC1R—skin cancer	0.000787	0.00547	CbGpPWpGaD
Alprostadil—Swelling—Fluorouracil—skin cancer	0.000782	0.00357	CcSEcCtD
Alprostadil—Cough—Vemurafenib—skin cancer	0.00077	0.00352	CcSEcCtD
Alprostadil—SLCO2B1—lymph node—skin cancer	0.00076	0.0096	CbGeAlD
Alprostadil—Hyperbilirubinaemia—Docetaxel—skin cancer	0.000755	0.00345	CcSEcCtD
Alprostadil—Erythema—Imiquimod—skin cancer	0.000753	0.00344	CcSEcCtD
Alprostadil—Rash—Vismodegib—skin cancer	0.000735	0.00336	CcSEcCtD
Alprostadil—PTGER1—GPCR ligand binding—PTCH2—skin cancer	0.000735	0.00511	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—PTCH2—skin cancer	0.000735	0.00511	CbGpPWpGaD
Alprostadil—Dermatitis—Vismodegib—skin cancer	0.000735	0.00335	CcSEcCtD
Alprostadil—ABCC5—Carbohydrate metabolism—CSPG4—skin cancer	0.000732	0.00509	CbGpPWpGaD
Alprostadil—Back pain—Imiquimod—skin cancer	0.000728	0.00333	CcSEcCtD
Alprostadil—Infection—Vemurafenib—skin cancer	0.000716	0.00327	CcSEcCtD
Alprostadil—Lethargy—Fluorouracil—skin cancer	0.000704	0.00322	CcSEcCtD
Alprostadil—Skin disorder—Vemurafenib—skin cancer	0.0007	0.0032	CcSEcCtD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000698	0.00485	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000698	0.00485	CbGpPWpGaD
Alprostadil—Nausea—Vismodegib—skin cancer	0.000693	0.00316	CcSEcCtD
Alprostadil—Injection site reaction—Docetaxel—skin cancer	0.000682	0.00312	CcSEcCtD
Alprostadil—Hypokalaemia—Temozolomide—skin cancer	0.000682	0.00311	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000679	0.00472	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RHOU—skin cancer	0.000675	0.00469	CbGpPWpGaD
Alprostadil—Syncope—Imiquimod—skin cancer	0.000675	0.00308	CcSEcCtD
Alprostadil—Acute coronary syndrome—Bleomycin—skin cancer	0.000675	0.00308	CcSEcCtD
Alprostadil—Hypotension—Vemurafenib—skin cancer	0.000673	0.00307	CcSEcCtD
Alprostadil—ABCC4—lymph node—skin cancer	0.000673	0.0085	CbGeAlD
Alprostadil—Myocardial infarction—Bleomycin—skin cancer	0.000671	0.00306	CcSEcCtD
Alprostadil—Influenza like illness—Docetaxel—skin cancer	0.000667	0.00304	CcSEcCtD
Alprostadil—Loss of consciousness—Imiquimod—skin cancer	0.000662	0.00302	CcSEcCtD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—skin cancer	0.000659	0.0414	CrCbGaD
Alprostadil—Cough—Imiquimod—skin cancer	0.000657	0.003	CcSEcCtD
Alprostadil—Cardiac arrest—Fluorouracil—skin cancer	0.000656	0.003	CcSEcCtD
Alprostadil—Haematuria—Bleomycin—skin cancer	0.000653	0.00298	CcSEcCtD
Alprostadil—Convulsion—Imiquimod—skin cancer	0.000652	0.00298	CcSEcCtD
Alprostadil—Hypertension—Imiquimod—skin cancer	0.00065	0.00297	CcSEcCtD
Alprostadil—Discomfort—Imiquimod—skin cancer	0.000633	0.00289	CcSEcCtD
Alprostadil—Sweating increased—Temozolomide—skin cancer	0.000631	0.00288	CcSEcCtD
Alprostadil—Dry mouth—Imiquimod—skin cancer	0.000627	0.00286	CcSEcCtD
Alprostadil—Bronchitis—Temozolomide—skin cancer	0.000623	0.00284	CcSEcCtD
Alprostadil—Haemoglobin—Bleomycin—skin cancer	0.000617	0.00282	CcSEcCtD
Alprostadil—Oedema—Imiquimod—skin cancer	0.000614	0.00281	CcSEcCtD
Alprostadil—Haemorrhage—Bleomycin—skin cancer	0.000614	0.00281	CcSEcCtD
Alprostadil—Hypoaesthesia—Bleomycin—skin cancer	0.000611	0.00279	CcSEcCtD
Alprostadil—Infection—Imiquimod—skin cancer	0.00061	0.00279	CcSEcCtD
Alprostadil—Shock—Imiquimod—skin cancer	0.000604	0.00276	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Temozolomide—skin cancer	0.000602	0.00275	CcSEcCtD
Alprostadil—Tachycardia—Imiquimod—skin cancer	0.0006	0.00274	CcSEcCtD
Alprostadil—Pollakiuria—Temozolomide—skin cancer	0.000598	0.00273	CcSEcCtD
Alprostadil—Skin disorder—Imiquimod—skin cancer	0.000597	0.00273	CcSEcCtD
Alprostadil—Sepsis—Docetaxel—skin cancer	0.000596	0.00272	CcSEcCtD
Alprostadil—Hyperhidrosis—Imiquimod—skin cancer	0.000594	0.00271	CcSEcCtD
Alprostadil—Hyperglycaemia—Temozolomide—skin cancer	0.000584	0.00267	CcSEcCtD
Alprostadil—ABCC4—Ectoderm Differentiation—SHH—skin cancer	0.000571	0.00397	CbGpPWpGaD
Alprostadil—Flushing—Bleomycin—skin cancer	0.00057	0.0026	CcSEcCtD
Alprostadil—Body temperature increased—Vemurafenib—skin cancer	0.00057	0.0026	CcSEcCtD
Alprostadil—Pharyngitis—Dactinomycin—skin cancer	0.000569	0.0026	CcSEcCtD
Alprostadil—Swelling—Docetaxel—skin cancer	0.000565	0.00258	CcSEcCtD
Alprostadil—Urinary tract infection—Temozolomide—skin cancer	0.000561	0.00256	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—SHH—skin cancer	0.000561	0.00389	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PTCH2—skin cancer	0.000558	0.00388	CbGpPWpGaD
Alprostadil—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000554	0.00253	CcSEcCtD
Alprostadil—Cardiac failure congestive—Docetaxel—skin cancer	0.000549	0.00251	CcSEcCtD
Alprostadil—Sinusitis—Temozolomide—skin cancer	0.000542	0.00247	CcSEcCtD
Alprostadil—Dyspepsia—Imiquimod—skin cancer	0.000541	0.00247	CcSEcCtD
Alprostadil—ABCC5—Fluoropyrimidine Activity—TP53—skin cancer	0.000536	0.00372	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000536	0.00372	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000536	0.00372	CbGpPWpGaD
Alprostadil—Erythema—Bleomycin—skin cancer	0.000535	0.00244	CcSEcCtD
Alprostadil—Flushing—Dactinomycin—skin cancer	0.000532	0.00243	CcSEcCtD
Alprostadil—PTGER1—GPCR ligand binding—MC1R—skin cancer	0.000531	0.00369	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—MC1R—skin cancer	0.000531	0.00369	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—SMO—skin cancer	0.000531	0.00369	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—PTCH1—skin cancer	0.000531	0.00369	CbGpPWpGaD
Alprostadil—Pain—Imiquimod—skin cancer	0.000525	0.0024	CcSEcCtD
Alprostadil—Acute coronary syndrome—Fluorouracil—skin cancer	0.000524	0.00239	CcSEcCtD
Alprostadil—Myocardial infarction—Fluorouracil—skin cancer	0.000521	0.00238	CcSEcCtD
Alprostadil—Haemoglobin—Temozolomide—skin cancer	0.000521	0.00238	CcSEcCtD
Alprostadil—Haemorrhage—Temozolomide—skin cancer	0.000518	0.00237	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—PTGER4—skin cancer	0.000517	0.00359	CbGpPWpGaD
Alprostadil—Urinary tract infection—Fluorouracil—skin cancer	0.000517	0.00236	CcSEcCtD
Alprostadil—Asthenia—Vemurafenib—skin cancer	0.000517	0.00236	CcSEcCtD
Alprostadil—Hypoaesthesia—Temozolomide—skin cancer	0.000516	0.00235	CcSEcCtD
Alprostadil—Pharyngitis—Temozolomide—skin cancer	0.000514	0.00235	CcSEcCtD
Alprostadil—Pruritus—Vemurafenib—skin cancer	0.00051	0.00233	CcSEcCtD
Alprostadil—Lethargy—Docetaxel—skin cancer	0.000508	0.00232	CcSEcCtD
Alprostadil—Urethral disorder—Temozolomide—skin cancer	0.000508	0.00232	CcSEcCtD
Alprostadil—Feeling abnormal—Imiquimod—skin cancer	0.000506	0.00231	CcSEcCtD
Alprostadil—Visual impairment—Temozolomide—skin cancer	0.000499	0.00228	CcSEcCtD
Alprostadil—Sinusitis—Fluorouracil—skin cancer	0.000499	0.00228	CcSEcCtD
Alprostadil—Erythema—Dactinomycin—skin cancer	0.000499	0.00228	CcSEcCtD
Alprostadil—Pain in extremity—Docetaxel—skin cancer	0.000498	0.00227	CcSEcCtD
Alprostadil—ABCC5—Carbohydrate metabolism—ENO2—skin cancer	0.000497	0.00346	CbGpPWpGaD
Alprostadil—Anaemia—Bleomycin—skin cancer	0.000494	0.00226	CcSEcCtD
Alprostadil—Diarrhoea—Vemurafenib—skin cancer	0.000493	0.00225	CcSEcCtD
Alprostadil—Body temperature increased—Imiquimod—skin cancer	0.000486	0.00222	CcSEcCtD
Alprostadil—Abdominal pain—Imiquimod—skin cancer	0.000486	0.00222	CcSEcCtD
Alprostadil—Flushing—Temozolomide—skin cancer	0.000481	0.0022	CcSEcCtD
Alprostadil—Haemoglobin—Fluorouracil—skin cancer	0.00048	0.00219	CcSEcCtD
Alprostadil—Rhinitis—Fluorouracil—skin cancer	0.000479	0.00219	CcSEcCtD
Alprostadil—Haemorrhage—Fluorouracil—skin cancer	0.000477	0.00218	CcSEcCtD
Alprostadil—Dizziness—Vemurafenib—skin cancer	0.000476	0.00218	CcSEcCtD
Alprostadil—Hypoaesthesia—Fluorouracil—skin cancer	0.000475	0.00217	CcSEcCtD
Alprostadil—Pharyngitis—Fluorouracil—skin cancer	0.000474	0.00216	CcSEcCtD
Alprostadil—Cough—Bleomycin—skin cancer	0.000467	0.00213	CcSEcCtD
Alprostadil—Anaemia—Dactinomycin—skin cancer	0.000461	0.00211	CcSEcCtD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000459	0.00319	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000459	0.00319	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000456	0.00317	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RHOU—skin cancer	0.000456	0.00317	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RHOU—skin cancer	0.000456	0.00317	CbGpPWpGaD
Alprostadil—Rash—Vemurafenib—skin cancer	0.000454	0.00207	CcSEcCtD
Alprostadil—Dermatitis—Vemurafenib—skin cancer	0.000454	0.00207	CcSEcCtD
Alprostadil—Headache—Vemurafenib—skin cancer	0.000451	0.00206	CcSEcCtD
Alprostadil—Erythema—Temozolomide—skin cancer	0.000451	0.00206	CcSEcCtD
Alprostadil—Discomfort—Bleomycin—skin cancer	0.00045	0.00205	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—MC1R—skin cancer	0.000445	0.00309	CbGpPWpGaD
Alprostadil—Asthenia—Imiquimod—skin cancer	0.000441	0.00201	CcSEcCtD
Alprostadil—Oedema—Bleomycin—skin cancer	0.000436	0.00199	CcSEcCtD
Alprostadil—Back pain—Temozolomide—skin cancer	0.000436	0.00199	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000436	0.00303	CbGpPWpGaD
Alprostadil—Pruritus—Imiquimod—skin cancer	0.000435	0.00198	CcSEcCtD
Alprostadil—Infection—Bleomycin—skin cancer	0.000434	0.00198	CcSEcCtD
Alprostadil—Nausea—Vemurafenib—skin cancer	0.000428	0.00195	CcSEcCtD
Alprostadil—Thrombocytopenia—Bleomycin—skin cancer	0.000427	0.00195	CcSEcCtD
Alprostadil—Diarrhoea—Imiquimod—skin cancer	0.00042	0.00192	CcSEcCtD
Alprostadil—Discomfort—Dactinomycin—skin cancer	0.00042	0.00192	CcSEcCtD
Alprostadil—Anaemia—Temozolomide—skin cancer	0.000417	0.0019	CcSEcCtD
Alprostadil—Erythema—Fluorouracil—skin cancer	0.000416	0.0019	CcSEcCtD
Alprostadil—Hypotension—Bleomycin—skin cancer	0.000408	0.00186	CcSEcCtD
Alprostadil—Oedema—Dactinomycin—skin cancer	0.000407	0.00186	CcSEcCtD
Alprostadil—Dizziness—Imiquimod—skin cancer	0.000406	0.00186	CcSEcCtD
Alprostadil—Infection—Dactinomycin—skin cancer	0.000404	0.00185	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—MC1R—skin cancer	0.000404	0.00281	CbGpPWpGaD
Alprostadil—Thrombocytopenia—Dactinomycin—skin cancer	0.000399	0.00182	CcSEcCtD
Alprostadil—Cough—Temozolomide—skin cancer	0.000394	0.0018	CcSEcCtD
Alprostadil—Convulsion—Temozolomide—skin cancer	0.000391	0.00178	CcSEcCtD
Alprostadil—Hypertension—Temozolomide—skin cancer	0.000389	0.00178	CcSEcCtD
Alprostadil—Rash—Imiquimod—skin cancer	0.000387	0.00177	CcSEcCtD
Alprostadil—Dermatitis—Imiquimod—skin cancer	0.000387	0.00177	CcSEcCtD
Alprostadil—Headache—Imiquimod—skin cancer	0.000385	0.00176	CcSEcCtD
Alprostadil—Anaemia—Fluorouracil—skin cancer	0.000384	0.00175	CcSEcCtD
Alprostadil—Discomfort—Temozolomide—skin cancer	0.000379	0.00173	CcSEcCtD
Alprostadil—PTGER1—GPCR ligand binding—SHH—skin cancer	0.000379	0.00263	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—SHH—skin cancer	0.000379	0.00263	CbGpPWpGaD
Alprostadil—Acute coronary syndrome—Docetaxel—skin cancer	0.000378	0.00173	CcSEcCtD
Alprostadil—Renal failure—Docetaxel—skin cancer	0.000377	0.00172	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—PTCH2—skin cancer	0.000377	0.00262	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PTCH2—skin cancer	0.000377	0.00262	CbGpPWpGaD
Alprostadil—Myocardial infarction—Docetaxel—skin cancer	0.000376	0.00172	CcSEcCtD
Alprostadil—Dry mouth—Temozolomide—skin cancer	0.000376	0.00172	CcSEcCtD
Alprostadil—Pain—Bleomycin—skin cancer	0.000373	0.0017	CcSEcCtD
Alprostadil—ABCC4—Fluoropyrimidine Activity—TP53—skin cancer	0.000372	0.00258	CbGpPWpGaD
Alprostadil—Oedema—Temozolomide—skin cancer	0.000368	0.00168	CcSEcCtD
Alprostadil—Infection—Temozolomide—skin cancer	0.000366	0.00167	CcSEcCtD
Alprostadil—Nausea—Imiquimod—skin cancer	0.000365	0.00167	CcSEcCtD
Alprostadil—Thrombocytopenia—Temozolomide—skin cancer	0.00036	0.00165	CcSEcCtD
Alprostadil—Convulsion—Fluorouracil—skin cancer	0.00036	0.00164	CcSEcCtD
Alprostadil—Feeling abnormal—Bleomycin—skin cancer	0.00036	0.00164	CcSEcCtD
Alprostadil—PTGER1—GPCR ligand binding—PTCH1—skin cancer	0.000359	0.00249	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—SMO—skin cancer	0.000359	0.00249	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—SMO—skin cancer	0.000359	0.00249	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—PTCH1—skin cancer	0.000359	0.00249	CbGpPWpGaD
Alprostadil—Skin disorder—Temozolomide—skin cancer	0.000358	0.00163	CcSEcCtD
Alprostadil—Hyperhidrosis—Temozolomide—skin cancer	0.000356	0.00163	CcSEcCtD
Alprostadil—Discomfort—Fluorouracil—skin cancer	0.00035	0.0016	CcSEcCtD
Alprostadil—PTGER1—GPCR ligand binding—PTGER4—skin cancer	0.000349	0.00243	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—PTGER4—skin cancer	0.000349	0.00243	CbGpPWpGaD
Alprostadil—Pain—Dactinomycin—skin cancer	0.000348	0.00159	CcSEcCtD
Alprostadil—Haemoglobin—Docetaxel—skin cancer	0.000346	0.00158	CcSEcCtD
Alprostadil—Rhinitis—Docetaxel—skin cancer	0.000346	0.00158	CcSEcCtD
Alprostadil—Body temperature increased—Bleomycin—skin cancer	0.000345	0.00158	CcSEcCtD
Alprostadil—Haemorrhage—Docetaxel—skin cancer	0.000345	0.00157	CcSEcCtD
Alprostadil—Hypoaesthesia—Docetaxel—skin cancer	0.000343	0.00157	CcSEcCtD
Alprostadil—Pharyngitis—Docetaxel—skin cancer	0.000342	0.00156	CcSEcCtD
Alprostadil—Oedema—Fluorouracil—skin cancer	0.000339	0.00155	CcSEcCtD
Alprostadil—Urethral disorder—Docetaxel—skin cancer	0.000338	0.00154	CcSEcCtD
Alprostadil—Infection—Fluorouracil—skin cancer	0.000337	0.00154	CcSEcCtD
Alprostadil—Feeling abnormal—Dactinomycin—skin cancer	0.000335	0.00153	CcSEcCtD
Alprostadil—Thrombocytopenia—Fluorouracil—skin cancer	0.000332	0.00152	CcSEcCtD
Alprostadil—Visual impairment—Docetaxel—skin cancer	0.000332	0.00152	CcSEcCtD
Alprostadil—Tachycardia—Fluorouracil—skin cancer	0.000331	0.00151	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—PTCH2—skin cancer	0.00033	0.00229	CbGpPWpGaD
Alprostadil—Dyspepsia—Temozolomide—skin cancer	0.000324	0.00148	CcSEcCtD
Alprostadil—Abdominal pain—Dactinomycin—skin cancer	0.000322	0.00147	CcSEcCtD
Alprostadil—Body temperature increased—Dactinomycin—skin cancer	0.000322	0.00147	CcSEcCtD
Alprostadil—Flushing—Docetaxel—skin cancer	0.00032	0.00146	CcSEcCtD
Alprostadil—Hypotension—Fluorouracil—skin cancer	0.000317	0.00145	CcSEcCtD
Alprostadil—Pain—Temozolomide—skin cancer	0.000315	0.00144	CcSEcCtD
Alprostadil—Asthenia—Bleomycin—skin cancer	0.000313	0.00143	CcSEcCtD
Alprostadil—Pruritus—Bleomycin—skin cancer	0.000309	0.00141	CcSEcCtD
Alprostadil—Feeling abnormal—Temozolomide—skin cancer	0.000303	0.00139	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000302	0.0021	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—MC1R—skin cancer	0.0003	0.00209	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—MC1R—skin cancer	0.0003	0.00209	CbGpPWpGaD
Alprostadil—Erythema—Docetaxel—skin cancer	0.0003	0.00137	CcSEcCtD
Alprostadil—Dyspepsia—Fluorouracil—skin cancer	0.000299	0.00136	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—PTGER4—skin cancer	0.000292	0.00203	CbGpPWpGaD
Alprostadil—Asthenia—Dactinomycin—skin cancer	0.000292	0.00133	CcSEcCtD
Alprostadil—Body temperature increased—Temozolomide—skin cancer	0.000291	0.00133	CcSEcCtD
Alprostadil—Abdominal pain—Temozolomide—skin cancer	0.000291	0.00133	CcSEcCtD
Alprostadil—Back pain—Docetaxel—skin cancer	0.00029	0.00133	CcSEcCtD
Alprostadil—Pain—Fluorouracil—skin cancer	0.00029	0.00132	CcSEcCtD
Alprostadil—Muscle spasms—Docetaxel—skin cancer	0.000288	0.00132	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—SHH—skin cancer	0.000288	0.002	CbGpPWpGaD
Alprostadil—Feeling abnormal—Fluorouracil—skin cancer	0.00028	0.00128	CcSEcCtD
Alprostadil—Diarrhoea—Dactinomycin—skin cancer	0.000279	0.00127	CcSEcCtD
Alprostadil—Anaemia—Docetaxel—skin cancer	0.000277	0.00127	CcSEcCtD
Alprostadil—Rash—Bleomycin—skin cancer	0.000275	0.00126	CcSEcCtD
Alprostadil—Dermatitis—Bleomycin—skin cancer	0.000275	0.00126	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—MC1R—skin cancer	0.000273	0.00189	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—MC1R—skin cancer	0.000273	0.00189	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—SMO—skin cancer	0.000273	0.00189	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PTCH1—skin cancer	0.000273	0.00189	CbGpPWpGaD
Alprostadil—Syncope—Docetaxel—skin cancer	0.000269	0.00123	CcSEcCtD
Alprostadil—Body temperature increased—Fluorouracil—skin cancer	0.000268	0.00122	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—PTGER4—skin cancer	0.000265	0.00184	CbGpPWpGaD
Alprostadil—Asthenia—Temozolomide—skin cancer	0.000264	0.00121	CcSEcCtD
Alprostadil—Loss of consciousness—Docetaxel—skin cancer	0.000264	0.0012	CcSEcCtD
Alprostadil—Cough—Docetaxel—skin cancer	0.000262	0.0012	CcSEcCtD
Alprostadil—Pruritus—Temozolomide—skin cancer	0.00026	0.00119	CcSEcCtD
Alprostadil—Convulsion—Docetaxel—skin cancer	0.00026	0.00119	CcSEcCtD
Alprostadil—Nausea—Bleomycin—skin cancer	0.000259	0.00118	CcSEcCtD
Alprostadil—Hypertension—Docetaxel—skin cancer	0.000259	0.00118	CcSEcCtD
Alprostadil—Rash—Dactinomycin—skin cancer	0.000257	0.00117	CcSEcCtD
Alprostadil—Diarrhoea—Temozolomide—skin cancer	0.000252	0.00115	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—GLI2—skin cancer	0.00025	0.00174	CbGpPWpGaD
Alprostadil—Dry mouth—Docetaxel—skin cancer	0.00025	0.00114	CcSEcCtD
Alprostadil—Oedema—Docetaxel—skin cancer	0.000245	0.00112	CcSEcCtD
Alprostadil—Dizziness—Temozolomide—skin cancer	0.000243	0.00111	CcSEcCtD
Alprostadil—Infection—Docetaxel—skin cancer	0.000243	0.00111	CcSEcCtD
Alprostadil—Nausea—Dactinomycin—skin cancer	0.000242	0.0011	CcSEcCtD
Alprostadil—Shock—Docetaxel—skin cancer	0.000241	0.0011	CcSEcCtD
Alprostadil—Pruritus—Fluorouracil—skin cancer	0.00024	0.0011	CcSEcCtD
Alprostadil—Thrombocytopenia—Docetaxel—skin cancer	0.00024	0.00109	CcSEcCtD
Alprostadil—Tachycardia—Docetaxel—skin cancer	0.000239	0.00109	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—MC1R—skin cancer	0.000238	0.00166	CbGpPWpGaD
Alprostadil—Skin disorder—Docetaxel—skin cancer	0.000238	0.00109	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—GLI1—skin cancer	0.000235	0.00163	CbGpPWpGaD
Alprostadil—Rash—Temozolomide—skin cancer	0.000232	0.00106	CcSEcCtD
Alprostadil—Diarrhoea—Fluorouracil—skin cancer	0.000232	0.00106	CcSEcCtD
Alprostadil—Dermatitis—Temozolomide—skin cancer	0.000232	0.00106	CcSEcCtD
Alprostadil—Headache—Temozolomide—skin cancer	0.000231	0.00105	CcSEcCtD
Alprostadil—Hypotension—Docetaxel—skin cancer	0.000229	0.00104	CcSEcCtD
Alprostadil—Dizziness—Fluorouracil—skin cancer	0.000224	0.00102	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—PTCH2—skin cancer	0.000223	0.00155	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTCH2—skin cancer	0.000223	0.00155	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SUFU—skin cancer	0.000223	0.00155	CbGpPWpGaD
Alprostadil—Nausea—Temozolomide—skin cancer	0.000219	0.000999	CcSEcCtD
Alprostadil—Dyspepsia—Docetaxel—skin cancer	0.000216	0.000984	CcSEcCtD
Alprostadil—ABCC5—Metabolism—PLIN2—skin cancer	0.000215	0.0015	CbGpPWpGaD
Alprostadil—Rash—Fluorouracil—skin cancer	0.000214	0.000977	CcSEcCtD
Alprostadil—Dermatitis—Fluorouracil—skin cancer	0.000214	0.000976	CcSEcCtD
Alprostadil—Headache—Fluorouracil—skin cancer	0.000213	0.00097	CcSEcCtD
Alprostadil—Pain—Docetaxel—skin cancer	0.000209	0.000956	CcSEcCtD
Alprostadil—ABCC5—Disease—CSPG4—skin cancer	0.000207	0.00144	CbGpPWpGaD
Alprostadil—Feeling abnormal—Docetaxel—skin cancer	0.000202	0.000921	CcSEcCtD
Alprostadil—Nausea—Fluorouracil—skin cancer	0.000202	0.00092	CcSEcCtD
Alprostadil—PTGIR—GPCR downstream signaling—PTGER4—skin cancer	0.000197	0.00137	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PTGER4—skin cancer	0.000197	0.00137	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—SHH—skin cancer	0.000194	0.00135	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—SHH—skin cancer	0.000194	0.00135	CbGpPWpGaD
Alprostadil—Body temperature increased—Docetaxel—skin cancer	0.000194	0.000884	CcSEcCtD
Alprostadil—Abdominal pain—Docetaxel—skin cancer	0.000194	0.000884	CcSEcCtD
Alprostadil—PTGIR—Signaling by GPCR—PTCH1—skin cancer	0.000184	0.00128	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—SMO—skin cancer	0.000184	0.00128	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—SMO—skin cancer	0.000184	0.00128	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PTCH1—skin cancer	0.000184	0.00128	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000182	0.00126	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PTGER4—skin cancer	0.000179	0.00125	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PTGER4—skin cancer	0.000179	0.00125	CbGpPWpGaD
Alprostadil—Asthenia—Docetaxel—skin cancer	0.000176	0.000802	CcSEcCtD
Alprostadil—ABCC5—Metabolism—CSPG4—skin cancer	0.000174	0.00121	CbGpPWpGaD
Alprostadil—Pruritus—Docetaxel—skin cancer	0.000173	0.000791	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—SHH—skin cancer	0.00017	0.00118	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GLI2—skin cancer	0.000169	0.00117	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GLI2—skin cancer	0.000169	0.00117	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RASA1—skin cancer	0.000169	0.00117	CbGpPWpGaD
Alprostadil—Diarrhoea—Docetaxel—skin cancer	0.000168	0.000765	CcSEcCtD
Alprostadil—Dizziness—Docetaxel—skin cancer	0.000162	0.000739	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—MC1R—skin cancer	0.000161	0.00112	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MC1R—skin cancer	0.000161	0.00112	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTCH1—skin cancer	0.000161	0.00112	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SMO—skin cancer	0.000161	0.00112	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GLI1—skin cancer	0.000159	0.0011	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GLI1—skin cancer	0.000159	0.0011	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTGER4—skin cancer	0.000157	0.00109	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000157	0.00109	CbGpPWpGaD
Alprostadil—Rash—Docetaxel—skin cancer	0.000154	0.000705	CcSEcCtD
Alprostadil—Dermatitis—Docetaxel—skin cancer	0.000154	0.000704	CcSEcCtD
Alprostadil—Headache—Docetaxel—skin cancer	0.000153	0.0007	CcSEcCtD
Alprostadil—PTGIR—Signaling Pathways—SUFU—skin cancer	0.000151	0.00105	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SUFU—skin cancer	0.000151	0.00105	CbGpPWpGaD
Alprostadil—Nausea—Docetaxel—skin cancer	0.000145	0.000664	CcSEcCtD
Alprostadil—ABCC5—Disease—SHH—skin cancer	0.000141	0.000979	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ENO2—skin cancer	0.000141	0.000979	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FOXO4—skin cancer	0.000139	0.000963	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000133	0.000925	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000127	0.000885	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ENO2—skin cancer	0.000118	0.00082	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FOXO4—skin cancer	0.000115	0.000798	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SHH—skin cancer	0.000115	0.000798	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SHH—skin cancer	0.000115	0.000798	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RASA1—skin cancer	0.000114	0.000793	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RASA1—skin cancer	0.000114	0.000793	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTCH1—skin cancer	0.000109	0.000756	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SMO—skin cancer	0.000109	0.000756	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SMO—skin cancer	0.000109	0.000756	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTCH1—skin cancer	0.000109	0.000756	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTGER4—skin cancer	0.000106	0.000736	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTGER4—skin cancer	0.000106	0.000736	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FOXO4—skin cancer	9.36e-05	0.00065	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FOXO4—skin cancer	9.36e-05	0.00065	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TERT—skin cancer	9.25e-05	0.000643	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—NRAS—skin cancer	9.17e-05	0.000638	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ERCC2—skin cancer	8.19e-05	0.000569	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—KRAS—skin cancer	7.9e-05	0.000549	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—NRAS—skin cancer	7.79e-05	0.000542	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TERT—skin cancer	7.67e-05	0.000533	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—BRAF—skin cancer	7.33e-05	0.000509	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—skin cancer	7.02e-05	0.000488	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ERCC2—skin cancer	6.86e-05	0.000476	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—HRAS—skin cancer	6.71e-05	0.000466	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—KRAS—skin cancer	6.71e-05	0.000466	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TERT—skin cancer	6.25e-05	0.000434	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TERT—skin cancer	6.25e-05	0.000434	CbGpPWpGaD
Alprostadil—ABCC5—Disease—BRAF—skin cancer	6.08e-05	0.000422	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRAS—skin cancer	5.7e-05	0.000396	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NRAS—skin cancer	5.47e-05	0.00038	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6—skin cancer	5.46e-05	0.000379	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—NRAS—skin cancer	5.27e-05	0.000366	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—NRAS—skin cancer	5.27e-05	0.000366	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—BRAF—skin cancer	4.95e-05	0.000344	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—BRAF—skin cancer	4.95e-05	0.000344	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—skin cancer	4.91e-05	0.000341	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—KRAS—skin cancer	4.71e-05	0.000327	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NRAS—skin cancer	4.6e-05	0.00032	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—KRAS—skin cancer	4.53e-05	0.000315	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—KRAS—skin cancer	4.53e-05	0.000315	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—skin cancer	4.18e-05	0.000291	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—skin cancer	4.11e-05	0.000286	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HRAS—skin cancer	4e-05	0.000278	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KRAS—skin cancer	3.96e-05	0.000275	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRAS—skin cancer	3.85e-05	0.000268	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRAS—skin cancer	3.85e-05	0.000268	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NRAS—skin cancer	3.82e-05	0.000265	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6—skin cancer	3.69e-05	0.000256	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6—skin cancer	3.69e-05	0.000256	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—skin cancer	3.52e-05	0.000245	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRAS—skin cancer	3.37e-05	0.000234	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KRAS—skin cancer	3.29e-05	0.000228	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6—skin cancer	3.22e-05	0.000224	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NRAS—skin cancer	3.11e-05	0.000216	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NRAS—skin cancer	3.11e-05	0.000216	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HRAS—skin cancer	2.79e-05	0.000194	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KRAS—skin cancer	2.68e-05	0.000186	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KRAS—skin cancer	2.68e-05	0.000186	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6—skin cancer	2.67e-05	0.000186	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—skin cancer	2.38e-05	0.000165	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—skin cancer	2.38e-05	0.000165	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRAS—skin cancer	2.28e-05	0.000158	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRAS—skin cancer	2.28e-05	0.000158	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6—skin cancer	2.18e-05	0.000151	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6—skin cancer	2.18e-05	0.000151	CbGpPWpGaD
